Characterization of topoisomerase II alpha and minichromosome maintenance protein 2 expression in anal carcinoma

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSCAPULATEMPO-NETO, Cristovam
dc.contributor.authorVEO, Carlos
dc.contributor.authorFREGNANI, Jose Humberto T. G.
dc.contributor.authorLORENZI, Adriana
dc.contributor.authorMAFRA, Allini
dc.contributor.authorMELANI, Armando G. F.
dc.contributor.authorLOAIZA, Edgar Antonio Aleman
dc.contributor.authorROSA, Luciana Albina Reis
dc.contributor.authorOLIVEIRA, Cristina Mendes De
dc.contributor.authorLEVI, Jose Eduardo
dc.contributor.authorLONGATTO-FILHO, Adhemar
dc.date.accessioned2017-06-09T15:43:33Z
dc.date.available2017-06-09T15:43:33Z
dc.date.issued2017
dc.description.abstractThe present study aimed to ascertain the significance of topoisomerase II alpha (TOP2A) and minichromosome maintenance protein (MCM) 2 expression in anal carcinoma. A total of 75 anal lesions were retrieved from the files of the Department of Pathology of Barretos Cancer Hospital (Barretos, Brazil) in order to verify the human papillomavirus (HPV) statuses of these lesions and characterize the immunohistochemical expression levels of TOP2A and MCM2 in anal carcinoma, as these are important markers for cervical HPV-induced lesions; their expression was also compared with respect to p16 and Ki-67. The vast majority of the cases tested positive for HPV16 (84%); 1 case tested positive for both HPV16 and HPV18. Positive HPV16 status was more frequent in early stages than in advanced stages (P=0.008). Positive immunohistochemical reactivity for MCM2 and TOP2A protein was observed in 71.6 and 100% of cases, respectively. Positive reactivity for p16 was significantly associated (P=0.001) with histological grade, and was more commonly expressed in squamous cell carcinoma than adenocarcinomas. HPV16 was strongly associated with positive p16 protein expression (76.6%). However, the high expression of Ki-67 combined with the high expression of p16 was predominantly observed in Stage III-IV cases. MCM2, TOP2A, p16 and Ki-67 exhibited intense positive staining in the anal lesions, indicating that these markers were significantly and constantly expressed in anal carcinoma.
dc.description.indexPubMed
dc.identifier.citationONCOLOGY LETTERS, v.13, n.3, p.1891-1898, 2017
dc.identifier.doi10.3892/ol.2017.5650
dc.identifier.eissn1792-1082
dc.identifier.issn1792-1074
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/20362
dc.language.isoeng
dc.publisherSPANDIDOS PUBL LTD
dc.relation.ispartofOncology Letters
dc.rightsrestrictedAccess
dc.rights.holderCopyright SPANDIDOS PUBL LTD
dc.subjectanal carcinoma
dc.subjectp16
dc.subjectKi-67
dc.subjectminichromosome maintenance protein 2
dc.subjecttopoisomerase II alpha
dc.subjecthuman papillomavirus
dc.subject.othersquamous intraepithelial lesions
dc.subject.otherhuman-papillomavirus dna
dc.subject.othercancer
dc.subject.otherneoplasia
dc.subject.otherp16
dc.subject.otherwomen
dc.subject.otherepidemiology
dc.subject.otherpathology
dc.subject.otherp16ink4a
dc.subject.othermen
dc.subject.wosOncology
dc.titleCharacterization of topoisomerase II alpha and minichromosome maintenance protein 2 expression in anal carcinoma
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalSCAPULATEMPO-NETO, Cristovam:Barretos Canc Hosp, Pio Fdn 12, Dept Pathol CSN, BR-14784400 Sao Paulo, SP, Brazil
hcfmusp.author.externalVEO, Carlos:Barretos Canc Hosp, Pio Fdn 12, Dept Surg, BR-14784400 Sao Paulo, SP, Brazil
hcfmusp.author.externalFREGNANI, Jose Humberto T. G.:Barretos Canc Hosp, Pio Fdn 12, Dept Pathol CSN, BR-14784400 Sao Paulo, SP, Brazil; Barretos Canc Hosp, Pio Fdn 12, Mol Oncol Res Ctr, BR-14784400 Sao Paulo, SP, Brazil
hcfmusp.author.externalLORENZI, Adriana:Barretos Canc Hosp, Pio Fdn 12, Mol Oncol Res Ctr, BR-14784400 Sao Paulo, SP, Brazil
hcfmusp.author.externalMAFRA, Allini:Barretos Canc Hosp, Pio Fdn 12, Mol Oncol Res Ctr, BR-14784400 Sao Paulo, SP, Brazil
hcfmusp.author.externalMELANI, Armando G. F.:Barretos Canc Hosp, Pio Fdn 12, Dept Surg, BR-14784400 Sao Paulo, SP, Brazil
hcfmusp.author.externalLOAIZA, Edgar Antonio Aleman:Barretos Canc Hosp, Pio Fdn 12, Dept Surg, BR-14784400 Sao Paulo, SP, Brazil
hcfmusp.citation.scopus8
hcfmusp.contributor.author-fmusphcLUCIANA REIS ROSA SACOMAN
hcfmusp.contributor.author-fmusphcCRISTINA MENDES DE OLIVEIRA
hcfmusp.contributor.author-fmusphcJOSE EDUARDO LEVI
hcfmusp.contributor.author-fmusphcADHEMAR LONGATTO FILHO
hcfmusp.description.beginpage1891
hcfmusp.description.endpage1898
hcfmusp.description.issue3
hcfmusp.description.volume13
hcfmusp.origemWOS
hcfmusp.origem.pubmed28454340
hcfmusp.origem.scopus2-s2.0-85011805105
hcfmusp.origem.wosWOS:000396998600131
hcfmusp.publisher.cityATHENS
hcfmusp.publisher.countryGREECE
hcfmusp.relation.referenceBala R, 2013, AM J SURG PATHOL, V37, P659, DOI 10.1097/PAS.0b013e31828706c0
hcfmusp.relation.referenceBean SM, 2007, AM J SURG PATHOL, V31, P555, DOI 10.1097/PAS.0b013e31802ca3f4
hcfmusp.relation.referenceBrown CA, 2012, J ONCOL, V2012, DOI 10.1155/2012/289315
hcfmusp.relation.referenceFirnhaber C, 2012, CURR HIV-AIDS REP, V9, P278, DOI 10.1007/s11904-012-0128-6
hcfmusp.relation.referenceGrulich AE, 2012, SEX HEALTH, V9, P504, DOI 10.1071/SH12070
hcfmusp.relation.referenceKreuter A, 2010, J AM ACAD DERMATOL, V63, P490, DOI 10.1016/j.jaad.2009.08.043
hcfmusp.relation.referenceLegarth R, 2013, SCAND J INFECT DIS, V45, P453, DOI 10.3109/00365548.2012.737476
hcfmusp.relation.referenceLongacre TA, 2008, ADV ANAT PATHOL, V15, P263, DOI 10.1097/PAP.0b013e318183234b
hcfmusp.relation.referenceLongatto A, 2005, INT J GYNECOL PATHOL, V24, P118, DOI 10.1097/01.RCT.0000157092.44680.25
hcfmusp.relation.referenceMachalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3
hcfmusp.relation.referenceNielsen A, 2012, INT J CANCER, V130, P1168, DOI 10.1002/ijc.26115
hcfmusp.relation.referencePalefsky JM, 2009, OBSTET GYN CLIN N AM, V36, P187, DOI 10.1016/j.ogc.2009.02.003
hcfmusp.relation.referencePinto AP, 2008, MODERN PATHOL, V21, P1067, DOI 10.1038/modpathol.2008.101
hcfmusp.relation.referencePirog EC, 2010, AM J SURG PATHOL, V34, P1449, DOI 10.1097/PAS.0b013e3181f0f52a
hcfmusp.relation.referenceRoelens J, 2012, CANCER CYTOPATHOL, V120, P294, DOI 10.1002/cncy.21205
hcfmusp.relation.referenceSAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
hcfmusp.relation.referenceSalit IE, 2009, CANCER EPIDEM BIOMAR, V18, P1986, DOI 10.1158/1055-9965.EPI-08-1141
hcfmusp.relation.referenceSerup-Hansen E, 2014, J CLIN ONCOL, V32, P1812, DOI 10.1200/JCO.2013.52.3464
hcfmusp.relation.referenceShi J, 2007, HUM PATHOL, V38, P1335, DOI 10.1016/j.humpath.2007.01.025
hcfmusp.relation.referenceThomas MK, 2011, VIROLOGY, V421, P114, DOI 10.1016/j.virol.2011.09.018
hcfmusp.relation.referenceUrgoiti GBR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108790
hcfmusp.relation.referenceValari O, 2011, GYNECOL ONCOL, V122, P505, DOI 10.1016/j.ygyno.2011.05.033
hcfmusp.relation.referenceVeo CAR, 2015, TUMOR BIOL, V36, P5399, DOI 10.1007/s13277-015-3205-9
hcfmusp.relation.referenceWalboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
hcfmusp.relation.referenceWalts Ann E, 2008, Clin Med Pathol, V1, P7
hcfmusp.relation.referenceWentzensen N, 2012, CLIN CANCER RES, V18, P4154, DOI 10.1158/1078-0432.CCR-12-0270
hcfmusp.relation.referenceWong AK, 2010, MODERN PATHOL, V23, P144, DOI 10.1038/modpathol.2009.143
hcfmusp.relation.referenceZandberg DP, 2013, CA-CANCER J CLIN, V63, P57, DOI 10.3322/caac.21167
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication5fc7cddf-df13-4211-be73-58587905fbab
relation.isAuthorOfPublicationafb00e79-5bb1-463b-9c3a-08241fb40797
relation.isAuthorOfPublication4ca67ecb-e5bc-4ad6-86ed-bea07644d7a8
relation.isAuthorOfPublication4401f59e-efe8-4a24-9f39-0b6bde3c72b7
relation.isAuthorOfPublication.latestForDiscovery5fc7cddf-df13-4211-be73-58587905fbab
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_SCAPULATEMPO-NETO_Characterization_of_topoisomerase_II_alpha_and_minichromosome_maintenance_2017.PDF
Tamanho:
704.75 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03